GSK plc has revealed late-breaking data from trials showing that its new treatment, depemokimab, leads to a significant 54% reduction in severe asthma attacks over 52 weeks, compared to placebo. This data was presented at the European Respiratory Society conference on September 9, 2024, highlighting the treatment's potential with just two doses a year.